<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791218</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5101071</org_study_id>
    <nct_id>NCT01791218</nct_id>
  </id_info>
  <brief_title>Surgical Pulmonary Vein Isolation Efficiency Study</brief_title>
  <acronym>FIN-PVI</acronym>
  <official_title>Concomitant Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation Patients Undergoing Elective Coronary Artery Bypass Grafting and Aortic Valve Replacement for Aortic Stenosis: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A substantial proportion of patients undergoing elective coronary artery bypass grafting have&#xD;
      a history of paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation has adverse&#xD;
      short-and long term postoperative effects. Pulmonary vein isolation (PVI) seems to be&#xD;
      effective treatment for paroxysmal atrial fibrillation. PVI can be done concomitantly with&#xD;
      coronary artery bypass grafting, aortic valve replacement for aortic stenosis and combination&#xD;
      of them. Procedure is well defined and safe.&#xD;
&#xD;
      There is a lack of convincing evidence of the effect on postoperative atrial fibrillation&#xD;
      burden, quality of life and symptoms especially in correlation with atrial fibrillation&#xD;
      paroxysms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough patients for study arms&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation burden</measure>
    <time_frame>Within one year after operative treatment</time_frame>
    <description>Atrial fibrillation burden is defined as the amount of atrial fibrillation on one week Holter monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom of symptomatic and asymptomatic atrial fibrillation after surgery</measure>
    <time_frame>Within one year after operative treatment</time_frame>
    <description>Atrial fibrillation is defined as atrial fibrillation paroxysm lasting at least 60 seconds.&#xD;
Freedom of atrial fibrillation is defined as duration of atrial fibrillation less than 0,5% of the one week Holter monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life (QOL) and symptoms, correlation of symptoms with atrial fibrillation</measure>
    <time_frame>Within one year after operative treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events after surgery in both arms</measure>
    <time_frame>Within one year after operative treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-arrhythmic treatment after surgery</measure>
    <time_frame>Within one year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to atrial fibrillation after surgery</measure>
    <time_frame>Within one year after operative treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioversion for the treatment of atrial fibrillation after surgery</measure>
    <time_frame>Within one year after operative treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other cardiovascular related events: death, stroke, cardiac infarction, need for revascularization and bleeding</measure>
    <time_frame>Within one year after operative treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CABG, AVR or CABG+AVR and PVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG, AVR or CABG+AVR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG, AVR or CABG+AVR and PVI</intervention_name>
    <arm_group_label>CABG, AVR or CABG+AVR and PVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG, AVR or CABG+AVR</intervention_name>
    <arm_group_label>CABG, AVR or CABG+AVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American College of Cardiology (ACC)/ American Heart Association (AHA) -Indications&#xD;
             for CABG&#xD;
&#xD;
          -  At least 2 ECG-verified (12-channel ECG, Holter telemetry) symptomatic paroxysmal&#xD;
             atrial fibrillation episodes within last 12 months&#xD;
&#xD;
          -  Duration of the atrial fibrillation episode must not exceed 1 week and it must reverse&#xD;
             to sinus rhythm spontaneously or by cardioversion&#xD;
&#xD;
          -  written and verbal consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cardiac surgery&#xD;
&#xD;
          -  Active pacemaker treatment&#xD;
&#xD;
          -  Active anti-arrhythmic treatment(AAD) class I and III&#xD;
&#xD;
          -  Contraindication to oral anticoagulant/heparin treatment&#xD;
&#xD;
          -  Ejection fraction less than 30 % (EF &lt; 30 %)assessed by transthoracic echocardiography&#xD;
&#xD;
          -  Left atrial diameter less than 55mm assessed by transthoracic echocardiography&#xD;
&#xD;
          -  Renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Heart valve disease requiring invasive treatment&#xD;
&#xD;
          -  Heart anomaly requiring regular controls and/or invasive treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <state>Eastern Finland</state>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Paroxysmal atrial fibrillation</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

